Dr. Peter Blume, D.P.M, F.A.C.F.A.S.

Dr. Peter Blume, D.P.M, F.A.C.F.A.S., is one of Connecticut’s most accomplished foot and ankle surgeons.

Dr. Peter Blume has spent decades helping patients suffering from foot and ankle problems. He is at the forefront of diabetic limb preservation and reconstruction, and has worked tirelessly to help his patients stand on their own two feet.

Dr. Peter Blume has been recognized 6 times by Connecticut magazine as one of “Connecticut’s Top Doctors”.

For diabetics facing the bleak prospect of losing a limb, Dr. Peter Blume might be their only hope. – New Haven Magazine

Dr. Blume sees patients at his clinic at 508 Blake Street in New Haven. He also operates at Yale-New Haven Hospital and Shoreline Surgery Center. He is certified by the American Board of Podiatric Surgery, the American Board of Podiatric Orthopedics and Primary Podiatric Medicine, and the American Board of Podiatric Surgery and holds Assistant Clinical Professor positions at the Yale University School of Medicine Departments of Orthopaedics, Anesthesia and Surgery.

Dr. Peter Blume is active in his field, publishing original research in over 120 publications and authoring many textbooks on podiatric surgery.

Appointments

(203) 397-0624

Specialty

Foot and Ankle Surgery
Diabetic Foot Reconstruction

Education

DOCTOR OF PODIATRIC MEDICINE, May 1992
New York College of Podiatric Medicine, New York, New York, 1988-1992

56) Zgonis,T.,Jolly G.P., Dr. Peter Blume,P.A.; External Fixation Use in Arthrodesis of the Foot and Ankle, Arthrodesis Techniques, Part I Clinics In Podiatric Medicine and Surgery of North America,Vol 22, No. 1, January 2004, 1-15;W.B. Saunders Company

11. Novartis Pharmaceuticals Corporation, 59 Route 10 East Hanover,NJ 07936-1080; Protocol;CSFO327KUS14, a randomized, open label, multicenter trial to investigate the efficacy and safety of 12 weeks of Oral Terbinafine(250-mgq.d.) With and without nail debridement in the treatment of onychomycosis.

16. Pfizer Pharmaceuticals Corp. Linezolid in the Treatment of Subjects with Complicated Skin and Soft Tissue Infections Proven to Be Due to Methicillin-resistant Staphylococcus Aureus. Protocol No. A 5951002, 10/04

24. CryoVascular Systems, Inc. Los Gatos, CA, Protocol #CVSi907/01: A randomized, multi-center study to evaluate the performance of the PolarCath™ Peripheral Dilatation System for the dilation of stenotic lesions in infrapopliteal arteries when treating the whole leg. 12/06

25. Pfizer Pharmaceuticals Group. New York, New York, Protocol # A5951002 Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to a methicillin-resistant Staphylococcus Aureus. A Phase IV clinical trial comparing clinical and bacterial efficacy and safety and tolerability of two treatment groups, linezolid vs. vancomycin. 6/07

26. Wyeth Pharmaceuticals. Collegeville, Pennsylvania, Protocol #3074A1-900- A Phase III, Multicenter, Randomized, Open-Label Comparison of the Safety and Efficacy of Tigecycline with that of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin and Skin Structure Infections: 6/07